Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MultiStem

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Rationale MultiStem® (HLM051) is one of the promising allogenic cell products for acute ischemic stroke with strong evidence. A… Expand
2016
2016
I schemic stroke is caused by a blockage of blood flow to the brain. A leading cause of death and disability globally, each year… Expand
2016
2016
Introduction: MultiStem is an adult, adherent, stem cell product, having shown safety and efficacy in other clinical indications… Expand
Highly Cited
2014
Highly Cited
2014
Background There is growing interest in neurorestorative and reparative therapies after acute stroke. MultiStem® is an allogeneic… Expand
  • figure 1
  • table 1
Highly Cited
2012
Highly Cited
2012
Rationale: MultiStem is an allogeneic bone marrow–derived adherent adult stem cell product that has shown efficacy in preclinical… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
2012
2012
Background: There is increasing evidence to suggest that some types of stem cells enhance recovery after stroke by exerting… Expand
2011
2011
Athersys (Nasdaq: ATHX) is a biopharmaceutical company engaged in the discovery and development of novel therapies designed to… Expand
2010
2010
Adoptive therapy with mesenchymal stem cells (MSC) is being developed as a promising approach in the treatment of graft-vs-host… Expand
Highly Cited
2009
Highly Cited
2009
The therapeutic benefits of adult adherent stem cells are currently being investigated in clinical trials for a variety of… Expand
Highly Cited
2004
Highly Cited
2004
The ecology and evolutionary potential of coast redwood (Sequoia sempervirens) is significantly influenced by the important role… Expand
  • figure I
  • table I
  • table 2
  • figure 2
  • figure 3